Press Releases

"Innovations in therapeutic strategies, coupled with a deeper understanding of breast cancer biology, will be essential for advancing personalized medicine and improving clinical outcomes.”

BUFFALO, NY - March 25, 2025 – A new review was published in Oncotarget, Volume 16, on March 13, 2025, titled “Signaling pathway dysregulation in breast cancer."

In this review article, Dinara Ryspayeva and colleagues from Brown University provide a detailed look at how breast cancer cells change the way... continue reading >>

"SABR is a well-established therapy in both the curative and metastatic setting, however, its ablative potential may not be as high as suggested by radiographic local control rates.”

BUFFALO, NY - March 21, 2025 – A new editorial was published in Oncotarget, Volume 16, on March 13, 2025, titled “No disease left behind."

In this editorial, Dr. Muzamil Arshad from the University of Chicago Medical Center and colleagues highlight a growing concern in cancer care: radiotherapy may leave behind... continue reading >>

"Our vision is to accelerate the future of precision oncology care.”

BUFFALO, NY - March 18, 2025 – A new precision oncology paper was published in Oncotarget, Volume 16, on March 12, 2025, titled “Worldwide Innovative Network (WIN) Consortium in Personalized Cancer Medicine: Bringing next-generation precision oncology to patients."

Led by Oncotarget Editor-in-Chief Dr. Wafik S. El-Deiry and a global team of researchers, this special publication highlights the groundbreaking work of the Worldwi... continue reading >>

Oncotarget is honored to participate in the American Association for Cancer Research (AACR) Annual Meeting 2025, scheduled for April 25-30 in Chicago.

BUFFALO, NY - March 17, 2025 – Impact Journals (Oncotarget’s publisher), is pleased to announce its participation as an exhibitor at the American Association for Cancer Research (AACR) Annual Meeting 2025. The meeting is scheduled for April 25-30, 2025, at the McCormick Place Convention Center in Chicago, Illinois.

The 2025 AACR Annual... continue reading >>

"These suggest that not an insignificant proportion of invasive cancers may also be overdiagnosed as indolent cancers with a very long lead time or cancers that spontaneously regress.”

BUFFALO, NY - March 12, 2025 – A new editorial was published in Oncotarget, Volume 16, on March 10, 2025, titled “COMETgazing - interesting insights, lessons for clinical practice and a call for more precision using the biomarkerSCOPE."

Dr. Mangesh A. Thorat, affiliated with Queen Mary University of London, Homer... continue reading >>

"Environmental exposures may cause genetic damage, lead to mutations in key genes, and/or block the DNA repair mechanisms increasing the risk of cancer.”

BUFFALO, NY - March 11, 2025 – A new editorial was published in Oncotarget, Volume 16, on March 10, 2025, titled “EXPOSOMES and GENES: The duo influencing CANCER initiation and progression."

In this editorial, Drs. Uzma Saqib, Katherine E. Ricks, Alexander G. Obukhov, and Krishnan Hajela from Devi Ahilya Vishwavidyalaya (DAVV) in Indore, India... continue reading >>

"Given the lethal nature of GBM and the limited efficacy of current therapies, the application of TIMPs and their engineered minimal variants represents a novel and potentially transformative approach to regulating MMP activity in GBM.”

BUFFALO, NY - March 3, 2025 – A new research paper was published in Oncotarget, Volume 16, on February 28, 2025, titled “Effect of TIMPs and their minimally engineered variants in blocking invasion and migration of brain cancer cells."

Elham Taheri and Maryam... continue reading >>

"To our knowledge, this is the first-in-animal preliminary study, which used a biocompatible electrospun membrane with the addition of autologous cells for ulcerative oral mucositis regeneration.”

BUFFALO, NY - February 25, 2025 – A new research paper was published in Oncotarget, Volume 16, on February 18, 2025, titled “Leukopenia, weight loss and oral mucositis induced by 5-Fluorouracil in hamsters’ model: A regenerative approach using electrospun poly(Lactic-co-Glycolic Acid) membrane."

Rese... continue reading >>

"We discovered several novel downstream p53 targets of potential clinical relevance [...]”

BUFFALO, NY - February 24, 2025 – A new research paper was published in Oncotarget, Volume 16, on February 18, 2025, titled “Robust p53 phenotypes and prospective downstream targets in telomerase-immortalized human cells."

Researchers Jessica J. Miciak, Lucy Petrova, Rhythm Sajwan, Aditya Pandya, Mikayla Deckard, Andrew J. Munoz, and Fred Bunz from the Sidney Kimmel Comprehensive Cancer Center and Johns... continue reading >>

“Using Panitumumab with metronomic Capecitabine is considered an accepted maintenance regimen in wild type Ras metastatic colorectal cancer regardless of the primary site.”

BUFFALO, NY - February 18, 2025 – A new research paper was published in Oncotarget, Volume 16, on February 12, 2025, titled “Could Panitumumab with very low dose Capecitabine be an option as a maintenance regimen."

In this study, researchers Doaa A. Gamal, Aiat Morsy, and Mervat Omar from Assiut University Hospital,... continue reading >>

“Our team has demonstrated the presence of SETDB1 abnormalities, particularly its amplification, through WES analysis of osteosarcoma human samples and cell lines.”

BUFFALO, NY - February 14, 2025 – A new review was published in Oncotarget, Volume 16, on February 12, 2025, titled “SETDB1 amplification in osteosarcomas: Insights from its role in healthy tissues and other cancer types."

Authors Elodie Verdier, Nathalie Gaspar, Maria Eugenia Marques Da Costa, and Antonin Marchais from the Gustave ... continue reading >>

“An uncommon side effect of allogeneic hematopoietic cell transplantation is donor cell-derived hematologic neoplasm (DCHN), which develops when donor hematopoietic cells undergo oncogenic transformation.”

BUFFALO, NY - February 10, 2025 – A new case report was published in Volume 16 of Oncotarget on February 5, 2025, titled “A case report of donor cell–derived hematologic neoplasms 9 years after allogeneic hematopoietic cell transplantation."

In this case report, Aleksandra... continue reading >>

“Here we present a case of a patient with stage IV CD-74-ROS1 fusion NSCLC discovered initially with RNA next generation sequencing (NGS) who acquired resistance to lorlatinib after 6 months on therapy through a novel RUFY1-RET fusion, detected only through RNA NGS.”

BUFFALO, NY - February 6, 2025 – A new case report was published in Volume 16 of Oncotarget on February 5, 2025, titled “Acquired RUFY1-RET rearrangement as a mechanism of resistance to lorlatinib in a patient with CD74-ROS1... continue reading >>

“Taken together, our results suggest that in addition to physiological age, comorbidities and unfavorable clinical traits, intense surgical manipulation from the tumor's extent, may result in greater tissue damage and elevated cfDNA release.”

BUFFALO, NY - January 27, 2025 – A new research paper was published in Oncotarget's Volume 16 on January 21, 2025, titled “Assessment of cfDNA release dynamics during colorectal cancer surgery."

Researchers from the University of Brasília investigated ... continue reading >>

“Human epidermal growth factor receptor 2 (HER2)-low breast cancer has recently emerged as a new clinical subtype of breast cancer, benefiting from treatment with novel anti-HER2 antibody-drug conjugates.”

BUFFALO, NY - January 22, 2025 – A new review was published in Oncotarget's Volume 16 on January 20, 2025, titled “Evolving concepts in HER2-low breast cancer: Genomic insights, definitions, and treatment paradigms."

Researchers Whitney L. Hensing, Emily L. Podany, James J. Sears,... continue reading >>

“The anti-correlation of PD-1 and KLRG1 expression in human tumor infiltrating CD8 T cells suggests the potential for combination therapy supra-additive benefits of anti-PD-1 and anti-KLRG1 therapies.”

BUFFALO, NY - January 21, 2025 – A new research paper was published in Oncotarget's Volume 16 on January 20, 2025, titled “Anti-correlation of KLRG1 and PD-1 expression in human tumor CD8 T cells."

The study, authored by Dr. Steven A. Greenberg from Harvard Medical School, has discovered a ... continue reading >>